The verdict
Our read at a glance.
Whether sincalide is understood as an approved diagnostic that makes the gallbladder and pancreas respond on cue for testing, rather than a treatment, including any appetite or weight use suggested by CCK's satiety role.
- The signal
- As a diagnostic, sincalide reliably triggers gallbladder contraction and pancreatic secretion, and it is a standard way to measure gallbladder ejection fraction during a nuclear gallbladder scan and to help test the pancreas.
- The unknown
- Mainly practical, such as the best infusion method to get reliable, comfortable results, and how to interpret borderline gallbladder ejection fractions. CCK's appetite biology has not translated into an approved weight or appetite treatment.
- Our read
- A long-standing diagnostic that borrows the gut hormone CCK to make the gallbladder squeeze on cue, mainly to measure gallbladder function. It is a testing tool, not a treatment; CCK's well-known role in fullness is interesting biology but has not become an approved appetite or weight drug, and sincalide is not used that way.
The mechanism
How it works.
Cholecystokinin (CCK) is a hormone the gut releases after a fatty or protein-rich meal; it tells the gallbladder to squeeze out bile and the pancreas to release digestive enzymes, and it also signals fullness to the brain. Sincalide is a synthetic copy of the active tail of CCK. Given by vein, it binds CCK receptors on the gallbladder and pancreas and makes them respond on demand, so during a scan doctors can watch the gallbladder contract and calculate how much it empties, or collect pancreatic fluid for testing. It is used to provoke a measurable response, not to treat a disease.
Safety & regulatory boundary
The consequential part.
Sincalide can cause short-lived abdominal cramping, nausea, and an urge to move the bowels, which a slow infusion reduces; it should be avoided in bowel obstruction and is not used in pregnancy because it can stimulate the uterus. It is a diagnostic agent, not a treatment, and despite CCK's role in fullness it is not an appetite or weight-loss drug. Kinevac is given by a clinician for testing.
What's next
What we're watching.
Standardized infusion and interpretation for gallbladder ejection fraction; CCK-pathway appetite research remains separate from this approved diagnostic use.
Context
Why this is discussed.
Sincalide is a lab-made piece of cholecystokinin (CCK), the gut hormone that empties the gallbladder after a fatty meal and also signals fullness to the brain. As a drug it is used to make the gallbladder contract on demand so doctors can measure how well it works.
The evidence base
15 cited references.
Regulatory & labels3
Bracco Diagnostics Inc. (FDA label) · 2023
MAIA Pharmaceuticals, Inc. (FDA label) · 2023
Fresenius Kabi USA, LLC (FDA label) · 2024
Indexed literature (PubMed)12
Vasireddi A et al. · Clin Nucl Med · 2022
Ziessman HA · J Nucl Med Technol · 2019
Ziessman HA et al. · J Nucl Med · 2010
Lalyre Y et al. · Dig Dis Sci · 1981
Guarasci DT et al. · Ann Pharmacother · 2004
Ziessman HA · Semin Nucl Med · 2012
Ziessman HA et al. · J Nucl Med · 1992
Siegel A et al. · Clin Nucl Med · 2000
Vyas PK et al. · J Magn Reson Imaging · 2002
Ziessman HA et al. · J Nucl Med · 2011
Krishnamurthy GT et al. · J Nucl Med · 2010
Ziessman HA · Semin Nucl Med · 2006
Keep reading